Vivesto

Vivesto EBITDA per Share

The EBITDA per Share of Vivesto (VIVE.ST) as of Oct 12, 2026 is -0.06 SEK. In the previous year, EBITDA per Share was -0.08 SEK — a change of -28.70% (higher).

EBITDA per Share

-0.06SEK

YoY

-28.70%

Last updated:

EBITDA per Share of Vivesto is 2025 -0.06 SEK. EBITDA per Share of Vivesto was 2024 -0.08 SEK. It decreases by -28.70% higher compared to the previous year.

The Vivesto EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.30 SEK
Jan 1, 2019
-0.03 SEK
Jan 1, 2020
-0.00 SEK
Jan 1, 2021
-0.21 SEK
Jan 1, 2022
-0.19 SEK
Jan 1, 2023
-0.14 SEK
Jan 1, 2024
-0.08 SEK
Jan 1, 2025
-0.06 SEK
The Vivesto EBITDA per Share history
YEAREBITDA per ShareYoY
-0.06SEK-28.70%
-0.08SEK-43.90%
-0.14SEK-25.12%
-0.19SEK-12.07%
-0.21SEK+8,088.94%
-0.00SEK-92.43%
-0.03SEK-88.67%
-0.30SEK-18.63%
-0.37SEK-50.25%
-0.74SEK-5.52%
-0.79SEK+8.61%
-0.72SEK—
Access this data via the Eulerpool API

Vivesto Stock analysis

What does Vivesto do? Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden. Vivesto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vivesto stock

EBITDA per Share of Vivesto is -0.06 SEK in 2025.

EBITDA per Share of Vivesto changed from -0.08 SEK to -0.06 SEK, representing a -28.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Vivesto since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — Vivesto

All Key Metrics — Vivesto